{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:36:59Z","timestamp":1795124219466,"version":"4.10.3"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tofacitinib, a pan\u2013Janus kinase inhibitor, and the Janus kinase 1\u2013preferential inhibitors Upadacitinib and Filgotinib are approved for the treatment of ulcerative colitis, yet their molecular mechanisms of action remain incompletely understood. Here, using dextran sulfate sodium\u2013induced and T cell transfer colitis models together with analyses of individuals with ulcerative colitis, we show that all three inhibitors ameliorate colitis in mice with macrophage-specific deletion of protein tyrosine phosphatase non-receptor type 2, a model characterized by hyperactive Janus kinase\u2013signal transducer and activator of transcription signaling. In contrast, only Upadacitinib and Filgotinib provide enhanced protection in wild-type mice \u2013 an effect that is lost upon genetic disruption of inflammasome signaling. Longitudinal single-cell transcriptomic analyses and immunostaining of intestinal biopsies further show that Upadacitinib reduces interleukin-1\u03b2 expression in vivo, which associates with clinical response. Thus, indirect suppression of inflammasome activity contributes to the efficacy of Janus kinase 1\u2013preferential inhibitors.<\/jats:p>","DOI":"10.1038\/s41467-026-71808-y","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T08:20:32Z","timestamp":1776673232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Indirect inhibition of the NLRP3-interleukin-1\u03b2 axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5596-0355","authenticated-orcid":false,"given":"Beibei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-0058","authenticated-orcid":false,"given":"Marianne R.","family":"Spalinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3380-8602","authenticated-orcid":false,"given":"Annalisa","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babett","family":"Steglich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Schwarzfischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Machicote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Pelczar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"P\u00f6hlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikolaj","family":"Nawrocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"B\u00f6ttcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayob","family":"Aleko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lis Noelia","family":"Velasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Wende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Stallbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Neuendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Grosshauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4639-4594","authenticated-orcid":false,"given":"Franziska","family":"Muscate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Douilhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Garcia","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morsal","family":"Sabihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Viehweger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorben","family":"Fr\u00fcndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8514-1395","authenticated-orcid":false,"given":"Nicola","family":"Gagliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-6792","authenticated-orcid":false,"given":"Amedeo","family":"Caflisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6729-1469","authenticated-orcid":false,"given":"Michael","family":"Scharl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9325-8227","authenticated-orcid":false,"given":"Samuel","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"71808_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L. & Colombel, J. F. Ulcerative colitis. Lancet 389, 1756\u20131770 (2017).","journal-title":"Lancet"},{"key":"71808_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","volume":"5","author":"V Jairath","year":"2020","unstructured":"Jairath, V. & Feagan, B. G. Global burden of inflammatory bowel disease. Lancet Gastroenterol. Hepatol. 5, 2\u20133 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"71808_CR3","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3389\/fimmu.2017.01373","volume":"8","author":"J Kempski","year":"2017","unstructured":"Kempski, J., Brockmann, L., Gagliani, N. & Huber, S. TH17 cell and epithelial cell crosstalk during inflammatory bowel disease and carcinogenesis. Front. Immunol. 8, 1373 (2017).","journal-title":"Front. Immunol."},{"key":"71808_CR4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet, L. et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am. J. Gastroenterol. 110, 1324\u20131338 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"71808_CR5","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","volume":"14","author":"SC Shah","year":"2016","unstructured":"Shah, S. C., Colombel, J. F., Sands, B. E. & Narula, N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 14, 1245\u20131255 e1248 (2016).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"71808_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq4473","volume":"14","author":"MF Neurath","year":"2022","unstructured":"Neurath, M. F. Targeting cytokines in inflammatory bowel disease. Sci. Transl. Med. 14, eabq4473 (2022).","journal-title":"Sci. Transl. Med."},{"key":"71808_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.gtc.2014.05.011","volume":"43","author":"BS Boland","year":"2014","unstructured":"Boland, B. S., Sandborn, W. J. & Chang, J. T. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol. Clin. North Am. 43, 603\u2013617 (2014).","journal-title":"Gastroenterol. Clin. North Am."},{"key":"71808_CR8","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41591-021-01520-5","volume":"27","author":"M Friedrich","year":"2021","unstructured":"Friedrich, M. et al. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat. Med. 27, 1970\u20131981 (2021).","journal-title":"Nat. Med."},{"key":"71808_CR9","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1136\/gutjnl-2018-316250","volume":"68","author":"V Singh","year":"2019","unstructured":"Singh, V. et al. Microbiota fermentation-NLRP3 axis shapes the impact of dietary fibres on intestinal inflammation. Gut 68, 1801\u20131812 (2019).","journal-title":"Gut"},{"key":"71808_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"71808_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/2326-6066.CIR-13-0081","volume":"1","author":"R Nowarski","year":"2013","unstructured":"Nowarski, R., Gagliani, N., Huber, S. & Flavell, R. A. Innate immune cells in inflammation and cancer. Cancer Immunol. Res. 1, 77\u201384 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"71808_CR12","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3748\/wjg.v29.i6.1026","volume":"29","author":"FEM Ali","year":"2023","unstructured":"Ali, F. E. M. et al. Therapeutic interventions target the NLRP3 inflammasome in ulcerative colitis: Comprehensive study. World J. Gastroenterol. 29, 1026\u20131053 (2023).","journal-title":"World J. Gastroenterol."},{"key":"71808_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","volume":"17","author":"A Salas","year":"2020","unstructured":"Salas, A. et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 17, 323\u2013337 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"71808_CR14","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1053\/j.gastro.2020.07.040","volume":"159","author":"M Parlato","year":"2020","unstructured":"Parlato, M. et al. Loss-of-function mutation in PTPN2 causes aberrant activation of JAK signaling via STAT and very early onset intestinal inflammation. Gastroenterology 159, 1968\u20131971 e1964 (2020).","journal-title":"Gastroenterology"},{"key":"71808_CR15","doi-asserted-by":"publisher","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","volume":"310","author":"S Danese","year":"2016","unstructured":"Danese, S., Grisham, M., Hodge, J. & Telliez, J. B. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am. J. Physiol. Gastrointest. Liver Physiol. 310, G155\u2013G162 (2016).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"71808_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct. Target. Ther. 6, 402 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"71808_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1126\/science.1087061","volume":"302","author":"PS Changelian","year":"2003","unstructured":"Changelian, P. S. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875\u2013878 (2003).","journal-title":"Science"},{"key":"71808_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer, D. M. et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J. Inflamm. 7, 41 (2010).","journal-title":"J. Inflamm."},{"key":"71808_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi, K., Laurence, A. & O\u2019Shea, J. J. Janus kinases in immune cell signaling. Immunol. Rev. 228, 273\u2013287 (2009).","journal-title":"Immunol. Rev."},{"key":"71808_CR20","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi, K. et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186, 4234\u20134243 (2011).","journal-title":"J. Immunol."},{"key":"71808_CR21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer, J. M. et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64, 970\u2013981 (2012).","journal-title":"Arthritis Rheum."},{"key":"71808_CR22","volume":"2016","author":"JA Singh","year":"2016","unstructured":"Singh, J. A. et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst. Rev. 2016, CD012183 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"71808_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68, 1\u201326 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"71808_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc1707500","volume":"377","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn, W. J., Su, C. & Panes, J. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 377, 496\u2013497 (2017).","journal-title":"N. Engl. J. Med."},{"key":"71808_CR25","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan, B. G. et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet 397, 2372\u20132384 (2021).","journal-title":"Lancet"},{"key":"71808_CR26","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese, S. et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 399, 2113\u20132128 (2022).","journal-title":"Lancet"},{"key":"71808_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad009","volume":"5","author":"R Panaccione","year":"2023","unstructured":"Panaccione, R. et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis 360 5, otad009 (2023).","journal-title":"Crohns Colitis 360"},{"key":"71808_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/ecco-jcc\/jjaa182","volume":"15","author":"MR Spalinger","year":"2021","unstructured":"Spalinger, M. R. et al. The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions. J. Crohns Colitis 15, 471\u2013484 (2021).","journal-title":"J. Crohns Colitis"},{"key":"71808_CR29","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1053\/j.gastro.2020.07.004","volume":"159","author":"MR Spalinger","year":"2020","unstructured":"Spalinger, M. R. et al. PTPN2 regulates interactions between macrophages and intestinal epithelial cells to promote intestinal barrier function. Gastroenterology 159, 1763\u20131777 e1714 (2020).","journal-title":"Gastroenterology"},{"key":"71808_CR30","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.celrep.2018.01.052","volume":"22","author":"MR Spalinger","year":"2018","unstructured":"Spalinger, M. R. et al. PTPN2 regulates inflammasome activation and controls onset of intestinal inflammation and colon cancer. Cell Rep. 22, 1835\u20131848 (2018).","journal-title":"Cell Rep."},{"key":"71808_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/ni1500","volume":"8","author":"A Brustle","year":"2007","unstructured":"Brustle, A. et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat. Immunol. 8, 958\u2013966 (2007).","journal-title":"Nat. Immunol."},{"key":"71808_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.bbrc.2009.03.034","volume":"382","author":"HK Lee","year":"2009","unstructured":"Lee, H. K. et al. Interleukin-6 induces proinflammatory signaling in Schwann cells: a high-throughput analysis. Biochem. Biophys. Res. Commun. 382, 410\u2013414 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"71808_CR33","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.celrep.2015.09.048","volume":"13","author":"S Ranjbar","year":"2015","unstructured":"Ranjbar, S., Haridas, V., Jasenosky, L. D., Falvo, J. V. & Goldfeld, A. E. A Role for IFITM Proteins in Restriction of Mycobacterium tuberculosis Infection. Cell Rep. 13, 874\u2013883 (2015).","journal-title":"Cell Rep."},{"key":"71808_CR34","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1172\/JCI83669","volume":"126","author":"MR Spalinger","year":"2016","unstructured":"Spalinger, M. R. et al. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J. Clin. Invest. 126, 1783\u20131800 (2016).","journal-title":"J. Clin. Invest."},{"key":"71808_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.chembiol.2023.09.016","volume":"31","author":"KA Teske","year":"2024","unstructured":"Teske, K. A. et al. Interrogating direct NLRP3 engagement and functional inflammasome inhibition using cellular assays. Cell Chem. Biol. 31, 349\u2013360 e346 (2024).","journal-title":"Cell Chem. Biol."},{"key":"71808_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714943","volume":"12","author":"H Zhu","year":"2021","unstructured":"Zhu, H. et al. Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2\/STAT3 pathway inhibition. Front Immunol. 12, 714943 (2021).","journal-title":"Front Immunol."},{"key":"71808_CR37","first-page":"6231","volume":"13","author":"J Hiscott","year":"1993","unstructured":"Hiscott, J. et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol. 13, 6231\u20136240 (1993).","journal-title":"Mol. Cell. Biol."},{"key":"71808_CR38","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-kappaB signaling in inflammation. Signal Transduct. Target Ther. 2, 17023 (2017).","journal-title":"Signal Transduct. Target Ther."},{"key":"71808_CR39","first-page":"4399","volume":"18","author":"D Li","year":"2018","unstructured":"Li, D., Ren, W., Jiang, Z. & Zhu, L. Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury. Mol. Med. Rep. 18, 4399\u20134409 (2018).","journal-title":"Mol. Med. Rep."},{"key":"71808_CR40","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1084\/jem.20172063","volume":"215","author":"C Wang","year":"2018","unstructured":"Wang, C. et al. Selective inhibition of the p38alpha MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J. Exp. Med. 215, 1315\u20131325 (2018).","journal-title":"J. Exp. Med."},{"key":"71808_CR41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature11986","volume":"496","author":"GM Tannahill","year":"2013","unstructured":"Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 496, 238\u2013242 (2013).","journal-title":"Nature"},{"key":"71808_CR42","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.2147\/JIR.S377499","volume":"15","author":"Y Luo","year":"2022","unstructured":"Luo, Y. et al. C\/EBPbeta promotes LPS-induced IL-1beta transcription and secretion in alveolar macrophages via NOD2 signaling. J. Inflamm. Res. 15, 5247\u20135263 (2022).","journal-title":"J. Inflamm. Res."},{"key":"71808_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-024-02541-3","volume":"24","author":"JP Li","year":"2025","unstructured":"Li, J. P. et al. NLRP3 inflammasome-modulated angiogenic function of EPC via PI3K\/Akt\/mTOR pathway in diabetic myocardial infarction. Cardiovasc. Diabetol. 24, 6 (2025).","journal-title":"Cardiovasc. Diabetol."},{"key":"71808_CR44","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.gastro.2020.04.074","volume":"159","author":"V Mitsialis","year":"2020","unstructured":"Mitsialis, V. et al. Single-cell analyses of colon and blood reveal distinct immune cell signatures of ulcerative colitis and Crohn\u2019s Disease. Gastroenterology 159, 591\u2013608 e510 (2020).","journal-title":"Gastroenterology"},{"key":"71808_CR45","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/s41590-024-01994-8","volume":"25","author":"T Thomas","year":"2024","unstructured":"Thomas, T. et al. A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease. Nat. Immunol. 25, 2152\u20132165 (2024).","journal-title":"Nat. Immunol."},{"key":"71808_CR46","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.7150\/thno.47860","volume":"11","author":"X Yang","year":"2021","unstructured":"Yang, X. et al. Tofacitinib restores the balance of gammadeltaTreg\/gammadeltaT17 cells in rheumatoid arthritis by inhibiting the NLRP3 inflammasome. Theranostics 11, 1446\u20131457 (2021).","journal-title":"Theranostics"},{"key":"71808_CR47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/ibd\/izy364","volume":"25","author":"LCS De Vries","year":"2019","unstructured":"De Vries, L. C. S. et al. A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function. Inflamm. Bowel Dis. 25, 647\u2013660 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"71808_CR48","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1097\/SLA.0000000000005571","volume":"278","author":"NM Patel","year":"2023","unstructured":"Patel, N. M. et al. Inhibition of the JAK\/STAT pathway with baricitinib reduces the multiple organ dysfunction caused by hemorrhagic shock in rats. Ann. Surg. 278, e137\u2013e146 (2023).","journal-title":"Ann. Surg."},{"key":"71808_CR49","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","volume":"64","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann, R. et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 64, 617\u2013629 (2012).","journal-title":"Arthritis Rheum."},{"key":"71808_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier, J. M. et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2, 23 (2018).","journal-title":"BMC Rheumatol."},{"key":"71808_CR51","doi-asserted-by":"crossref","unstructured":"Boneschansker, L. & Ananthakrishnan, A. N. Massachusetts General Hospital Crohn\u2019s And Colitis Center Collaborators. Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data. Clin. Gastroenterol. Hepatol. 21, 2427\u20132429.e2421 (2023).","DOI":"10.1016\/j.cgh.2023.03.040"},{"key":"71808_CR52","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1084\/jem.20111453","volume":"209","author":"M Coccia","year":"2012","unstructured":"Coccia, M. et al. IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J. Exp. Med. 209, 1595\u20131609 (2012).","journal-title":"J. Exp. Med."},{"key":"71808_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcmgh.2022.03.003","volume":"14","author":"M Liso","year":"2022","unstructured":"Liso, M. et al. Interleukin 1beta blockade reduces intestinal inflammation in a murine model of tumor necrosis factor-independent ulcerative colitis. Cell. Mol. Gastroenterol. Hepatol. 14, 151\u2013171 (2022).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"71808_CR54","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaci.2020.09.003","volume":"147","author":"L Zhou","year":"2021","unstructured":"Zhou, L. et al. Excessive deubiquitination of NLRP3-R779C variant contributes to very-early-onset inflammatory bowel disease development. J. Allergy Clin. Immunol. 147, 267\u2013279 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"71808_CR55","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","volume":"15","author":"A Tapia-Abellan","year":"2019","unstructured":"Tapia-Abellan, A. et al. MCC950 closes the active conformation of NLRP3 to an inactive state. Nat. Chem. Biol. 15, 560\u2013564 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"71808_CR56","doi-asserted-by":"publisher","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","volume":"285","author":"C Juliana","year":"2010","unstructured":"Juliana, C. et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J. Biol. Chem. 285, 9792\u20139802 (2010).","journal-title":"J. Biol. Chem."},{"key":"71808_CR57","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1074\/jbc.M113.515080","volume":"289","author":"Y He","year":"2014","unstructured":"He, Y. et al. 3,4-methylenedioxy-beta-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J. Biol. Chem. 289, 1142\u20131150 (2014).","journal-title":"J. Biol. Chem."},{"key":"71808_CR58","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang, H. et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 214, 3219\u20133238 (2017).","journal-title":"J. Exp. Med."},{"key":"71808_CR59","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"RC Coll","year":"2019","unstructured":"Coll, R. C. et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat. Chem. Biol. 15, 556\u2013559 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"71808_CR60","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.immuni.2010.03.003","volume":"32","author":"MH Zaki","year":"2010","unstructured":"Zaki, M. H. et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32, 379\u2013391 (2010).","journal-title":"Immunity"},{"key":"71808_CR61","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1084\/jem.20160462","volume":"214","author":"V Neudecker","year":"2017","unstructured":"Neudecker, V. et al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. J. Exp. Med. 214, 1737\u20131752 (2017).","journal-title":"J. Exp. Med."},{"key":"71808_CR62","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2024.04.024","volume":"370","author":"A Favaron","year":"2024","unstructured":"Favaron, A. et al. Can in vitro\/in silico tools improve colonic concentration estimations for oral extended-release formulations? A case study with upadacitinib. J. Control. Release 370, 182\u2013194 (2024).","journal-title":"J. Control. Release"},{"key":"71808_CR63","doi-asserted-by":"crossref","unstructured":"Verstockt, B. et al. Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis. J. Crohns Colitis 19, jjaf063 (2025).","DOI":"10.1093\/ecco-jcc\/jjaf063"},{"key":"71808_CR64","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1053\/j.gastro.2016.08.055","volume":"151","author":"DS Shouval","year":"2016","unstructured":"Shouval, D. S. et al. Interleukin 1beta mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency. Gastroenterology 151, 1100\u20131104 (2016).","journal-title":"Gastroenterology"},{"key":"71808_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17179-4","volume":"11","author":"JA Bibby","year":"2020","unstructured":"Bibby, J. A. et al. Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate. Nat. Commun. 11, 3412 (2020).","journal-title":"Nat. Commun."},{"key":"71808_CR66","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/ecco-jcc\/jjac190.0033","volume":"17","author":"T Raine","year":"2023","unstructured":"Raine, T. et al. OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO). J. Crohn\u2019s. Colitis 17, i43\u2013i46 (2023).","journal-title":"J. Crohn\u2019s. Colitis"},{"key":"71808_CR67","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/mi.2014.122","volume":"8","author":"MR Spalinger","year":"2015","unstructured":"Spalinger, M. R. et al. PTPN2 controls differentiation of CD4(+) T cells and limits intestinal inflammation and intestinal dysbiosis. Mucosal Immunol. 8, 918\u2013929 (2015).","journal-title":"Mucosal Immunol."},{"key":"71808_CR68","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 e3529 (2021).","journal-title":"Cell"},{"key":"71808_CR69","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u2013W97 (2016).","journal-title":"Nucleic Acids Res."},{"key":"71808_CR70","doi-asserted-by":"publisher","unstructured":"Liu, B. et al. Indirect inhibition of the NLRP3-interleukin-1\u03b2 axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitis. University of Hamburg, https:\/\/doi.org\/10.25592\/uhhfdm.18257 (2026).","DOI":"10.25592\/uhhfdm.18257"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71808-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71808-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71808-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:02:53Z","timestamp":1781827373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71808-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71808"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71808-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. has shares and is co-founder of Recolony AG, Zurich, CH and has shares in PharmaBiome AG, Zurich, CH. M.S. served as Advisor for Abbvie, Gilead, Fresenius, Topadur, Takeda, Roche and Celltrion. M.S. received speaker\u2019s honoraria from Janssen, Falk Pharma, Vifor Pharma, Pileje and Bromatech. M.S. received research grants from Abbvie, Takeda, Gilead, Gnubiotics, Roche, Axalbion, Pharmabiome, Topadur, Basilea, MBiomics, Storm Therapeutics, LimmatTech, Zealand Pharma, NodThera, Calypso Biotech, Pileje, Herbodee, Vifor. S.H. served as Advisor for Abbvie and Janssen. S.H. received speaker\u2019s honoraria from Abbvie, Janssen, Falk Pharma, Ferring, Galapagos. S.H. received an Ecco-Pfizer research grant. N.G. reports financial support from F. Hoffmann\u2013La Roche and from GlaxoSmithKline (GSK); the support from GSK is for work unrelated to the topic of this manuscript. All support is administered via UKE. The remaining authors declare no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5429"}}